2 249

Cited 21 times in

Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry

Authors
 Jaewon Oh  ;  Seok-Min Kang  ;  Namki Hong  ;  Jong-Chan Youn  ;  Seongwoo Han  ;  Eun-Seok Jeon  ;  Myeong-Chan Cho  ;  Jae-Joong Kim  ;  Byung-Su Yoo  ;  Shung Chull Chae  ;  Byung-Hee Oh  ;  Dong-Ju Choi  ;  Myung-Mook Lee  ;  Kyu-Hyung Ryu 
Citation
 International Journal of Cardiology, Vol.168(5) : 4739-4743, 2013 
Journal Title
 International Journal of Cardiology 
ISSN
 0167-5273 
Issue Date
2013
Abstract
BACKGROUND: Hemoconcentration is a surrogate marker of effective decongestion and diuresis therapy. Recently, hemoconcentration has been associated with decreased mortality and rehospitalization in heart failure (HF) patients. However, the prognostic power of hemoconcentration in a large sample-sized HF cohort was limited until now. METHODS AND RESULTS: We analyzed data from hospitalized patients with acute heart failure (AHF) that were enrolled in the Korean Heart Failure Registry(n=2,357). The primary end point was a composite of all-cause mortality and HF rehospitalization during the follow-up period (median=347, interquartile range=78-744 days).Hemoconcentration, defined as an increased hemoglobin level between admission and discharge, was presented in 1,016 AHF patients (43.1%). In multivariable logistic regression, hemoglobin, total cholesterol, and serum glucose levels at admission, and ischemic HF, were significant determinants for hemoconcentration occurrence. The Kaplan-Meier curve showed that event-free survival was significantly higher in the hemoconcentration group compared to the non-hemoconcentration group (65.1% vs. 58.1%, log rank p<0.001). In multiple Cox proportional hazard analysis, hemoconcentration was an independent predictor of the primary end point after adjusting for other HF risk factors (hazard ratio=0.671, 95% confidence interval=0.564-0.798, p<0.001). CONCLUSIONS: Hemoconcentration during hospitalization was a prognostic marker of fewer clinical events in the AHF cohort. Therefore, this novel surrogate marker will help in the risk stratification of AHF patients.
Full Text
http://www.sciencedirect.com/science/article/pii/S0167527313014666
DOI
10.1016/j.ijcard.2013.07.241
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Min(강석민) ORCID logo https://orcid.org/0000-0001-9856-9227
Oh, Jae Won(오재원) ORCID logo https://orcid.org/0000-0002-4585-1488
Youn, Jong Chan(윤종찬)
Hong, Nam Ki(홍남기) ORCID logo https://orcid.org/0000-0002-8246-1956
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88403
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse